Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 anticipated ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differ ...

Zentalis Pharmaceuticals, Inc. (ZNTL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role of Cyclin E1/CDK2 activation predicting sensitivity to azenosertib published in npj Precision Oncology Corporate event to be held on January 29, 2025 to provide updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Stock Market LLC (The Nasdaq Global Market) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th ...

Overview of the Recent Transaction FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LI.C (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares. This move reflects a significant change in the firm's investment strategy regarding Zentalis, with the transaction carried out at a price of $3 .68 per s ...

Shares of Zentalis Pharmaceuticals (ZNTL) gained 13.6% on Monday after it announced that the FDA has lifted the partial clinical hold previously imposed on three studies of the company's lead product candidate, azenosertib, for three different cancer indications. The decision was based on the regulatory body's review of Zentalis' complete response package, which included a comprehensive safety assessment of the azenosertib program. Zentalis' azenosertib, a potentially first-in-class oral WEE1 inhibitor, is ...

Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study activities across the azenosertib development program as quickly as possible. Also Read: Zentalis Gea ...

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of azenosertib, the Company's novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the Company to r ...

Shares of Zentalis Pharmaceuticals, Inc. (ZNTL) have plunged 71.7% in the past three months against the industry's growth of 6.2%. The company is developing its lead product candidate, azenosertib, a potentially first-in-class WEE1 inhibitor, as a monotherapy and in combination with other therapies for treating different types of cancer indications, including solid tumors and ovarian cancer. In June 2024, the FDA placed a partial clinical hold on three studies evaluating azenosertib for three different canc ...